The Importance of Median Progression-Free Survival in Oncology Clinical Trials

Tanios S. Bekaii-Saab

The Importance of Median Progression-Free Survival in Oncology Clinical Trials

Interview with the Innovators

Pancreatic Cancer Patient Education

Videos

Featuring:

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this third installment, Michael Pishvaian, MD, PhD, and Tanios Bekaii-Saab, MD, discuss why median progression-free survival is so important when considering the various transformational trials in pancreatic cancer.

Featuring:

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

The Importance of Median Progression-Free Survival in Oncology Clinical Trials

Featuring:

Featuring:

Related Articles

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content